Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix

Posted: November 22, 2021 at 1:57 am

FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids

Link:
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix

Related Posts